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Vitamin B12 (cobalamin (Cbl)), in the cofactor forms methyl-
Cbl and adenosyl-Cbl, is required for the function of the essen-
tial enzymes methionine synthase and methylmalonyl-CoA
mutase, respectively. Cbl enters mammalian cells by receptor-
mediated endocytosis of protein-bound Cbl followed by lyso-
somal export of free Cbl to the cytosol and further processing to
these cofactor forms. The integral membrane proteins LMBD1
andABCD4 are required for lysosomal release of Cbl, andmuta-
tions in the genes LMBRD1 and ABCD4 result in the cobalamin
metabolism disorders cblF and cblJ. We report a new (fifth)
patientwith the cblJ disorderwhopresented at 7days of agewith
poor feeding, hypotonia, methylmalonic aciduria, and elevated
plasma homocysteine and harbored the mutations c.1667_
1668delAG [p.Glu556Glyfs*27] and c.1295G>A [p.Arg432Gln]
in the ABCD4 gene. Cbl cofactor forms are decreased in fibro-
blasts from this patient but could be rescued by overexpression
of either ABCD4 or, unexpectedly, LMBD1. Using a sensitive
live-cell FRET assay, we demonstrated selective interaction
between ABCD4 and LMBD1 and decreased interaction when
ABCD4 harbored the patient mutations p.Arg432Gln or
p.Asn141Lys or when artificial mutations disrupted the ATPase
domain. Finally, we showed that ABCD4 lysosomal targeting
depends on co-expression of, and interaction with, LMBD1.
These data broaden the patient and mutation spectrum of cblJ
deficiency, establish a sensitive live-cell assay to detect the
LMBD1–ABCD4 interaction, and confirm the importance of
this interaction for proper intracellular targeting of ABCD4 and
cobalamin cofactor synthesis.
VitaminB12 (cobalamin (Cbl)4) is required for the function of
two enzymes, cytosolic methionine synthase (MS) and mito-
chondrial methylmalonyl-CoA mutase (MUT), and a sophisti-
cated pathway of cellular transport andmodification is required
for production and targeting of their appropriate cofactor
forms. This elaborate pathway is likely an evolutionary re-
sponse to the scarcity and reactivity of Cbl (1, 2) and presents
Cbl with a cellular odyssey to reach these targets. Cbl’s intracel-
lular journey begins with receptor-mediated endocytosis after
binding of Cbl-bound transcobalamin to the transcobalamin
receptor (3). Once internalized, Cbl is released from transco-
balamin as the pH lowers in the transition from the endosome
to lysosome. Free Cbl is transported out of the lysosome and
into the cytosol, a process that requires two integral membrane
proteins, LMBD1 and ABCD4 (4, 5). Within the cytosol, Cbl is
bound and processed by the protein MMACHC (6, 7) and, via
interaction with MMACHC, targeted by MMADHC (8, 9)
either (i) to cytosolicMS, with subsequent conversion tometh-
yl-Cbl (MeCbl) requiringMS reductase (encoded byMTRR), or
(ii) to themitochondria, for uptake by an unknownmechanism.
Within the mitochondria, Cbl is adenosylated by MMAB to
form the functional cofactor adenosyl-Cbl (AdoCbl) and then
transferred to MUT (10), an action closely controlled by
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MMAA, which blocks or ejects non-functional Cbl forms (11).
The molecular actions of these post lysosomal pathway pro-
teins are now quite well elucidated, enabled by their solubil-
ity and accessibility to recombinant production; however,
those of the membrane-bound proteins, viz. LMBD1 and
ABCD4, remain elusive.
Approximately 30 years ago Rosenblatt et al. (12) published
the finding of a B12-defective patient whose fibroblasts were
unable to release Cbl from the lysosome. This disorder, termed
cblF (methylmalonic aciduria and homocystinuria, cblF type;
OMIM: #277380; Ref. 13), was eventually found to be due to
defective LMBD1 (LMBRD1 gene) (5), an integral membrane
protein with homology to the lipocalin-1-interacting mem-
brane receptor LIMR. LMBD1 colocalizes with LAMP1 (5), a
lysosomal membrane protein, providing a direct link between
the mutated protein and the organelle of the defect. However,
the way inwhich LMBD1 facilitates lysosomal Cbl release is not
yet clear. By homology to LIMR, which binds and internalizes
lipocalins, small secreted proteins that bind protoporphin IX
among other ligands (14), a receptor/transporter role has been
suggested (5). Furthermore, and of as yet unknown significance,
a recent study suggested a small percentage (3.4%) of LMBD1
is retained at the plasmamembrane and is important for insulin
receptor internalization (15). Thus far all 16 patients with
recessive mutations in LMBRD1 have presented with the cblF
type disorder (5, 16–19) without apparent glucose metabolism
dysregulation.
More recently, a second protein involved in lysosomal Cbl
release was discovered. Deficiency of ABCD4, an ABC-trans-
porter family protein stemming from truncating or missense
mutations in the ABCD4 gene, results in methylmalonic acidu-
ria and homocystinuria, cblJ type (OMIM: #614857) (4).
Although in patient fibroblasts cblJ deficiency phenotypically
mimics cblF, including loss of Cbl transport out of the lyso-
some, somatic complementation assays and the inability of
overexpressed LMBD1 to rescue cobalamin cofactor synthesis
in cblJ cells firmly establish them as separate disorders. Only
four patients have been described in detail thus far with cblJ
deficiency. The first two described patients presented within
the first weeks of life with feeding difficulties, hypotonia, respi-
ratory distress (patient 1), and an atrial septal defect (patient 2)
among many further symptoms (4). Both patients were
heterozygous for a splicing or truncating mutation and a mis-
sense mutation, which in the case of patient 2 was also found to
affect splicing (4). By contrast, patients three (20) and four (21)
both harbored the same homozygous missense mutation
(c.423CG, p.Asn141Lys), presented between 8 and 12 years of
age, and had less severe symptoms, including mild macrocytic
anemia and hyperpigmentation. Presentation with hyperpig-
mentation is unusual for patients with inborn errors of cobala-
min metabolism, although there are rare reports of hyperpig-
mentation in general vitamin B12 deficiency (e.g. Refs. 22–24).
Hyperpigmentation has not been noted in any of the 16 patients
with LMBD1deficiency (5, 16–19), although some patients had
skin rash or eczema.
Although other ABCD family members (1–3) are peroxi-
somal (25–28), ABCD4 lacks the N-terminal peroxisomal tar-
geting hydrophobic motif (29). Overexpressed ABCD4 has
been identified in the ER (30); however, over-expression in the
presence of LMBD1 resulted in lysosomal targeting (31). Lyso-
somal targeting is in line with previous identification of colo-
calization between ABCD4, LMBD1, and LAMP1, a classical
lysosomalmarker (4), its identification in a large scale proteom-
ics study of lysosomal membrane proteins (32), and the cellular
inability to release Cbl from the lysosomes in the case of either
the cblF or cblJ defect. LMBD1-dependent targeting of ABCD4
alongwith the cellular and biochemicalmimicry of ABCD4 and
LMBD1 dysfunction suggests they interact, a possibility par-
tially supported by surface plasmon resonance of purified pro-
teins in vitro (33).
Here, we report a new patient, the fifth with cblJ deficiency
who presented with mild disease due to a truncating and amis-
sensemutation in theABCD4 gene. The unusual ability of over-
expressed LMBD1 to correct the cellular phenotype in fibro-
blasts in this patient prompted us to further investigate the
cellular location and interaction of these partner proteins.
Using a live cell fluorescent resonance energy transfer (FRET)
assay, we provide experimental evidence of the LMBD1–
ABCD4 interaction in human fibroblasts and highlight the
crucial importance of this interaction and its disturbance by
patient mutations or mutations that disrupt ATPase activity
of ABCD4. We further confirm the lysosomal localization of
LMBD1 and targeting of ABCD4 to the lysosome in the pres-
ence of LMBD1, which is prevented when the ability of
ABCD4 to bind LMBD1 is broken. These data suggest an
intimate relationship between ABCD4 and LMBD1 and
describe how ABCD4 mutations affect the interaction with
LMBD1, impair lysosomal targeting, and ultimately ABCD4
function.
Results
A new patient with cblJ deficiency
The first child of non-consanguineous parents was born at
full term after an uneventful pregnancy. Neonatal screening
suggested methylmalonic aciduria, with increased propionyl-
carnitine. At 7 days of age he presented with hypotonia and
poor feeding. Methylmalonic acid in the urine was 403 mmol/
mol of creatinine, and plasma total homocysteine was 88.6
mol/liter. These clinical and biochemical findings are consis-
tent with vitamin B12 deficiency or disturbed B12 metabolism,
although the clinical symptoms are unspecific at this age. From
the first week of life the patient received 1 mg of vitamin B12
every 2 days and a protein-restricted diet. Eight days after the
start of therapy methylmalonic acid levels decreased to 77
mmol/mol creatinine (reference 3). A followup neurological
examination was normal.
The patient was lost to followup between the ages of 2 and 10
years. During this period, vitamin B12 (1 mg/d) per os was reg-
ularly taken. His visit at the age of 10 years was motivated by a
deterioration of vision (6/10 and 1/10). Eye investigations
showed a retinal dystrophy and a loss of the scotopic reaction at
the electroretinogram. Neurophysiologic evaluation (electro-
myography, conduction velocity, evoked potential) suggested a
peripheral neuropathy and a slight involvement of the pyrami-
dal tract. Retinopathy as well as peripheral neuropathy and
ABCD4 and LMBD1 interaction disruption
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involvement of the spinal tract are common in early onset cblC
deficiency and other defects of methylcobalamin synthesis
(such as cblD, cblE, or cblG), whereas in nutritional vitamin B12
deficiency retinopathy is rarely found. Brain and spine MRI
were normal. He also presentedwith regular pain andweakness
of the lower limbs as well as hypopigmentation of the hair.
Increased total homocysteine, urinary methyl malonate, mac-
rocytosis, and albuminuria were present at that time (Table 1).
Treatment was intensified: folic acid was added and hydroxo-
cobalamin was given daily by intramuscular injections during
the first week, then three times per week, and finally once a
week. The biochemical tests improved progressively and nor-
malized after 4 months.
Cobalamin uptake and coenzyme synthesis (CCS) assay of
cultured primary fibroblasts of the patient showed elevated
uptake of radioactive cyanocobalamin compared with controls
but severely decreased production of the cofactor forms
AdoCbl andMeCbl (supplemental Table S2), suggesting either
cblF or cblJ deficiency.Molecular genetic investigation revealed
no mutations in LMBRD1, the gene responsible for the cblF
defect, whereas a 2-base-pair deletion resulting in a frameshift
(c.1667_1668delAG, p.Glu556Glyfs*27) was found in trans
with a 1-base-pair substitution, resulting in a missense muta-
tion (c.1295GA p.Arg432Gln) in ABCD4, the gene responsi-
ble for the cblJ complementation group. The missense muta-
tion is predicted to be “deleterious” by SWIFT and “probably
damaging” by PolyPhen and has been identified in only 1 out of
121,412 alleles in the EXaC database (exac.broadinstitute.org)5
(64). Therefore, this patient has been assigned as the fifth patient
with the cblJ defect (cblJ05). As found with another reported
patient with the cblJ defect (20), incorporation of [14C]propionate
and formation of [14C]methionine from [14C]formatewerewithin
reference ranges (data not shown) andwere, therefore, too high to
allow somatic complementation analysis.
Unusual correction of intracellular cblJ deficiency with LMBD1
overexpression
To further evaluate intracellular deficiency in cblF and cblJ
patient fibroblasts, we attempted cellular cobalamin cofactor
synthesis rescue using overexpression of wild type (WT)
untagged versions of either LMBD1 or ABCD4 using the
pTracer-CMV2 vector (Fig. 1A). Immortalized fibroblasts from
cblJ01 and cblJ02 have rescued production of AdoCbl and
MeCbl in the presence of overexpression of ABCD4 but not
LMBD1. A representative immortalized cblF cell line was par-
tially rescued by ABCD4 but has much greater production of
both AdoCbl and MeCbl after LMBD1 overexpression, consis-
tent with previous results (4). By contrast, synthesis of both
cofactor forms was equally rescued by overexpression of either
ABCD4 or LMBD1 in immortalized cblJ05 fibroblasts.
The combination of cofactor synthesis rescue by either
LMBD1 or ABCD4 overexpression in the cblJ05 fibroblasts
with the almost identical clinical and biochemical presentation
of cblF and cblJ patients (4) led us to suggest that ABCD4 and
LMBD1 may operate in concert to perform their biochemical
functions. To test this hypothesis, we generated plasmids con-
sisting of LMBD1-tagged C-terminally with enhanced green
fluorescent protein (GFP) and ABCD4-tagged C-terminally
with far-red fluorescent protein (fRFP). To ensure that these
fusion constructs (LMBD1-GFP and ABCD4-fRFP) repre-
sented physiologically functional proteins, we repeated the
CCS assay after transfection of cblF and cblJ02 with both con-
5 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Figure 1. Cobalamin cofactor synthesis rescue in cblF and cblJ patient fibroblasts. A, transfection of LMBRD1 (cblF) and ABCD4 (cblJ) WT alleles in
immortalized fibroblasts of the two original patients with cblJ defect (cblJ01 and cblJ02), cblJ05, and a patient with the cblF defect. Transfections with
empty vector (vector only) were used as negative controls. Mean plus S.D. is shown. B, cblF patient fibroblasts were transfected with DNA coding for
fluorescent protein only (GFP), untagged LMBD1 in pTracer-CMV2 (LMBD1), or fluorescently tagged-LMBD1 (LMBD1-GFP). cblJ patient fibroblasts were
transfected with DNA coding for fluorescent protein only (fRFP only), untagged ABCD4 in pTracer-CMV2 (ABCD4), or fluorescently tagged-ABCD4
(ABCD4-fRFP)  LMBD1-GFP. Immortalized control fibroblasts without transfection (n  23) are shown for comparison. Bars represent the mean and
error bars S.D. from at least three separate experiments.
Table 1
Normalization of clinical parameters after intense vitamin B12 treat-
ments
MCV, mean corpuscular volume; N, normal.
Parameter
First visit at the
age of 10 years
4 months
later
Total homocysteine (mol/liter) 57 8.4
Methylmalonic acid (mmol/mol creatinine) 64 2
Vitamin B12 (ng/liter) 560 2000
MCV of RBC (fl) 98 87
Methionine (mol/liter) 17 (N) 30 (N)
Albuminuria (mg/g creatinine) 94 17
ABCD4 and LMBD1 interaction disruption
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structs (Fig. 1B). cblJ02 was chosen here because all other cblJ
fibroblast cell lines carry at least one missense mutation in
ABCD4 (Table 2), potentially resulting in residual endogenous
mutant ABCD4 protein which may affect experimental results.
Control fibroblasts are able to generate 20% AdoCbl (5%,
range: 12–28%) and 38%MeCbl (11%, range: 22–55%) as total
cellular cobalamin from [57Co]cyanocoblamin. When trans-
fected with constructs coding for GFP-only (cblF) or fRFP-only
(cblJ), patient fibroblasts produced almost negligible amounts
of both cofactors. However, production of each cofactor was
elevated after expression of the fluorescently tagged proteins
(LMBD1-GFP and ABCD4-fRFP) to similar levels as overex-
pressed with untagged protein (LMBD1 or ABCD4) from
pTracer-CMV2. Therefore, although there are currently no
direct assays of either LMBD1 or ABCD4 function, the fluores-
cently tagged LMBD1 and ABCD4 proteins are functional as
assessed by their ability to rescue AdoCbl andMeCbl synthesis
in the respective deficient cell lines.
Intracellular targeting of ABCD4 and LMBD1
As a first test to identify whether LMBD1 and ABCD4 are
required for mutual function, we examined their subcellular
location using confocal microscopy. After co-transfection of
LMBD1-GFP and ABCD4-fRFP into control fibroblasts, both
proteins were found to co-localize with each other as well as
with endogenous lysosomal LAMP1 (Fig. 2A). However, when
expressed separately, LMBD1 extensively colocalized with
LAMP1 (Fig. 2B), whereas ABCD4 and LAMP1 showed very
little colocalization and only at the cell periphery (Fig. 2C).
These results were confirmed by comparison of each protein
with LysoTracker, whereby LMBD1 and LAMP1, but not
ABCD4, showed extensive lysosomal localization (supplemen-
tal Fig. S1). After site-directed mutagenesis to incorporate the
mis-targeting mutation p.Tyr232Ala into LMBD1-GFP, shown
previously to inhibit LMBD1 internalization from the plasma
membrane to the lysosome (15), ABCD4-fRFP was found to
follow LMBD1 to its altered cellular location in both HeLa cells
and control fibroblasts (supplemental Fig. S2). This confirms
that ABCD4 targeting is at least partially mediated by LMBD1
and suggests that in the absence of overexpressed LMBD1, the
low levels of endogenous LMBD1 present in these cells are
unable to efficiently direct ABCD4 to the lysosome. Although
overexpressed ABCD4 alone has been previously described to
be found sequestered in the endoplasmic reticulum (30, 31), we
Figure 2. Colocalization of ABCD4-fRFP and LMBD1-GFP with endogenous LAMP1. A, confocal microscopy images of immortalized control fibroblasts co-
transfectedwithLMBD1-GFPandABCD4-fRFPandstainedwithLAMP1antibodyto localize lysosomes.B, LMBD1-GFPoverexpressioncomparedwithLAMP1staining.
Regions inwhichbothproteins co-localize appear yellow in themerged image.C, ABCD4-fRFPoverexpression comparedwith LAMP1 staining. The absenceof yellow
in themerged image indicates a lack of colocalization. ForA–C, thewhite scale bar is 10m.Arrowheads depict examples of overlap between all threemarkers.
Table 2
Description of patients and cell lines used
Cell line Patient no. Defect Mutation 1 Mutation 2 Reference
WG4066 cblJ01 cblJ c.955AG (p.Tyr319Cys) c.1747_1748insCT (p.Glu583Leufs*9) 4
cblJ02 cblJ02 cblJ c.542 1GT (p.Asp143_Ser181del) c.1456GT (p.Gly443-Ser485del) 4
cblJ03 cblJ c.423CG (p.Asn141Lys) c.423CG (p.Asn141Lys) 20
cblJ04 cblJ c.423CG (p.Asn141Lys) c.423CG (p.Asn141Lys) 21
cblJ05 cblJ05 cblJ c.1295GA (p.Arg432Gln) c.1667_1668delAG (p.Glu556Glyfs*27) This paper
cblF cblF c.1405delG (p.Asp469fs*38) c.1405delG (p.Asp469fs*38) 16
ABCD4 and LMBD1 interaction disruption
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did not find significant overlap of individually overexpressed
ABCD4-fRFP with a marker of the ER in control fibroblasts
(supplemental Fig. S3) or HeLa cells (data not shown). Of the
organelles surveyed, including early (EEA), late (Rab7), and
recycling (Rab11) endosomes as well as ER (HSP47), peroxi-
somes (ABCD3), and autophagosomes (LC3), ABCD4-fRFP
overlapped best with autophagosomes (supplemental Fig. S3).
Of note, this overlapwas foundmostly in the perinuclear region
(supplemental Fig. S3), the region inwhich therewas poor colo-
calization between ABCD4-fRFP and LAMP1 (Fig. 2C). Finally,
although co-expression of ABCD4 and LMBD1 was required
for significant lysosomal targeting of ABCD4 (Fig. 2), it did not
lead to increased cofactor synthesis in cblJ-deficient fibroblasts
compared with overexpression of ABCD4 alone (Fig. 1B).
Specific detection of the LMBD1-GFP and ABCD4-fRFP
interaction by fluorescence-activated cell sorter (FACS)-based
FRET
Given the importance of LMBD1 for lysosomal targeting of
ABCD4, we utilized a sensitive live cell assay to detect protein-
protein interaction based on FRET of the fluorescently labeled
proteins using FACS. Because FACS-based FRET, to our
knowledge, has been until now only performed using the
CFP::YFP conjugate pair (e.g. Refs. 34–38), we tested the ame-
nability of thismethod to ourGFP and fRFP pair as FRETdonor
and acceptor, respectively. In immortalized control fibroblasts
gated according to forward and side scatter (FSC/SSC) to iden-
tify only living cells (supplemental Fig. S4), the FRET-positive
signal (FRET) could be clearly distinguished in cells trans-
fected with a fusion construct of GFP tethered to fRFP
(GFP::fRFP) from signal found in untransfected fibroblasts
(negative), those expressing GFP or fRFP only, or those co-
transfected with GFP and fRFP (supplemental Fig. S4). Thus,
with appropriate gating, 75.5% of live cells transfected with the
fusion construct were found to be FRET, comparedwith 0.1%
when cellswere co-transfectedwithGFP and fRFP (supplemen-
tal Fig. S4). This clearly demonstrates the feasibility of using a
flow cytometer to detect FRET signal from the chosen fluo-
rescent proteins.
As with the GFP::fRFP fusion protein, we constructed a
fusion protein of LMBD1-GFP::ABCD4-fRFP (supplemental
Fig. S5) to function as a positive control in our further FRET
assays. After transfection of this construct into fibroblasts, 48%
of cells had an elevated signal in the GFP channel (GFP, Fig.
3A, %GFP), and 47%of cells had an elevated signal in the far-red
channel (fRFP; Fig. 3A, % fRFP). From the GFP and fRFP
cells, the mean intensity (MI) of the FRET signal, a measure of
FRET independent of our final gating (see below), was 140 (Fig.
3A, FRET intensity). This fusion protein gave a linear GFP ver-
sus FRET signal (Fig. 3B), which we gated as FRET, and
encompassed 24% of all cells and 59% of cells that were both
GFP and fRFP (Fig. 3C). When co-transfected, LMBD1-
GFP and ABCD4-fRFP showed similar transfection efficiencies
(37%GFP and 46% fRFP cells) to those of the fusion protein
and anMI of 114 (Fig. 3A). The GFP versus FRET signal pattern
Figure 3. Analysis of protein interactions in immortalized fibroblasts using flow cytometry-based FRET. A, histogram view of GFP intensity (% GFP) and fRFP
intensity (% fRFP) for each (co)transfection. Cells were considered GFP or fRFP if intensity was102 in each respective channel. From cells that were GFP and
fRFP, the MI of signal in the FRET channel was calculated. B, FRET intensity plotted against GFP intensity, where FRET cells are defined by a stick-shaped gate
encompassing signal from conjugated LMBD1–ABCD4 above the intensity threshold of 102 for both GFP and FRET (left panel). Pictures depict a representative
experiment, and thenumber in purple represents the averagepercentage of all live cells that are FRET for each condition (n 3).C, bar graphof the percent FRET
positive cells from those cells thatwereGFP and fRFP for each condition.Data represent at least three separate experiments. The error bar represents S.D.D, table
summarizing the data presented in panels B andC.
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was also similar, with 17% of all cells (Fig. 3B) and 50% of the
GFP and fRFP cells (Fig. 3C) falling within the FRET gate.
LMBD1-GFP and ABCD4-fRFP transfected separately and,
although well expressed, resulted in no (0.5%) FRET signal
(supplemental Fig. S6). To establish the specificity of this assay,
we analyzed the FRET signal against two lysosomal membrane
proteins, LAMP1 and ABCB9, that are not involved in Cbl
transport. Each protein conjugated to fRFP was co-transfected
with LMBD1-GFP or conjugated to GFP co-transfected with
ABCD4-fRFP. These alternate lysosomal membrane proteins,
although well expressed (Fig. 3A), gave FRET signals in all
cells ranging from 0 to 4% (Fig. 3B) and in GFP and fRFP
cells ranging from 1 to 8% (Fig. 3C), with FRET MIs of 23–43
(Fig. 3A), all clearly below co-transfected LMBD1 and ABCD4.
The complete FACS data is summarized in the table in Fig. 3D
and allow us to conclude that LMBD1-GFP and ABCD4-fRFP
have a specifically increased FRET signal, indicative of protein-
protein interaction.
ABCD4 patient and ATPase-disruptingmutations reduce
interaction and function
Based on the ability to sensitively detect interaction between
ABCD4 and LMBD1, we investigated whether the missense
mutation found in our patient (p.Arg432Gln) affected this
interaction (Fig. 4). We further chose to reproduce the effects
of the missense mutation p.Asn141Lys (p.N141K), which has
been found homozygously in two patients with the cblJ-type
defect (20, 21). Additionally, we generated twomutations in the
ATPase domain: p.Asp548Asn (p.D548N) in the Walker B
motif, whichwas previously shown to inhibit function (4), and a
double mutation, p.Gly426_Lys427delinsAlaLeu (p.G426A/
K427L) in the Walker A motif, to test whether disruption of
ATPase activity in this protein affected interaction with
LMBD1. For a schematic of the position of these mutations in
ABCD4, see Fig. 5A. Because no disease-causing missense
mutations have been found thus far in LMBD1 and it is as yet
unclearwhich domainsmight be required for LMBD1 function,
we did not produce any mutations in this protein.
After co-transfectionwith LMBD1-GFP, all fourmutant pro-
teins resulted in markedly decreased FRET signals compared
with WT ABCD4-fRFP (Fig. 4A), of which the ATPase double
mutation p.Gly426_Lys427delinsAlaLeu resulted in essentially
no FRET signal (Fig. 4A). This despite good expression of all
mutant constructs (supplemental Fig. S7) and only slightly
decreased FRET signal for the single mutations p.Gly426Ala
and p.Lys427Leu (supplemental Fig. S8). To investigate
whether this decreased interaction with LMBD1 resulted in
altered cellular localization of ABCD4, we performed confocal
microscopy.Wild-type ABCD4-fRFP showed strongly overlap-
ping signal with LMBD1-GFP, which was quantified using the
Pearson correlation co-efficient (PCC  0.93). The ABCD4
proteins harboring the two patient mutations were also pre-
dominantly found in the same cellular location as LMBD1
(PCC 0.83–0.86, Fig. 4B). ABCD4 proteins with the ATPase
mutation p.Asp548Asn appeared to be inside as well as on the
Figure 4. Missense mutations from patients and in the ATPase domain of ABCD4 can disrupt interaction with LMBD1. A, left, FRET intensity plotted
against GFP intensity, where FRET cells are defined as in Fig. 3B. The number in purple represents the percentage of all live cells that are FRET for each
condition.Right,bar graphof thepercent FRET-positive cells from those cells thatwereGFP and fRFP for each condition. For eachmutation%FRET cells
are given as percent wild-type ABCD4. Data represent at least three separate experiments. The error bar represents S.D. B, merged confocal images of
fibroblasts co-transfectedwith combinations ofmutant ABCD4-fRFP andwild-type LMBD1-GFP. Regions inwhich both proteins co-localize appear yellow. The
white square indicates the zoomed-in region below. The scale bar is 10 m. Numbers indicate Pearson correlation coefficient. C, rescue of AdoCbl and MeCbl
synthesis in immortalized fibroblasts of an ABCD4-deficient (cblJ02) patient after transfection withmutant ABCD4-fRFP proteins. The error bar represents S.D.
Data represent a single experiment performed in triplicate.
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membrane of the lysosome (Fig. 4B), suggesting in addition to
proper lysosomal localization, they may be internalized, per-
haps for degradation. Consistent with a complete loss of
FRET signal, ABCD4-fRFP with the p.Gly426_Lys427
delinsAlaLeu mutation only partial overlapped with LMBD1
(PCC  0.54, Fig. 4C). The results of both of these tech-
niques are consistent with results of the CCS assay of ABCD4
protein function, whereby ABCD4 harboring the mutations
p.Asn141Lys and p.Arg432Glnwere less able to rescue cofactor
synthesis in cblJ fibroblasts than WT protein, p.Asp548Asn
had even decreased rescue and p.Gly426_Lys427delinsAlaLeu
resulted in essentially no rescue at all.
Homologymodeling of the ATPase domain of ABCD4 accounts
for the effect of patient fifthmutations
To assess how the p.Arg432Gln mutation might alter the
interaction between ABCD4 and LMBD1, we built an atomic-
resolution model of the ATPase domain of human ABCD4
using homology modeling of the crystal structure of the multi-
ple sugar binding transportATP-binding protein fromPyrococ-
cus horikoshii (ProteinData Bank (PDB) ID 2D62) as a template
and refined using PCAT1 from Ruminiclostridium thermocel-
lum (PDB ID 4RY2) (Fig. 5B). Interestingly, the resulting 3D
model predicts that Arg-432 is on a solvent-accessible surface,
and its side chain extends outwardly and away from the mod-
eled nucleotide, in agreement with a potential role in physical
interaction with another protein but not in nucleotide hydro-
lysis. In contrast, Lys-427 andAsp-548 extend toward the phos-
phate groups of the bound nucleotide, consistent with their
roles in the Walker A and B motifs, respectively (supplemental
Fig. S9B). Finally, the frameshift mutation p.Glu556Glyfs*27
carried by the second allele of patient five should delete two
-helices and three  strands (supplemental Fig. S9), thus dis-
rupting the ATPase domain structure and resulting in a null
allele of ABCD4.
Discussion
A fifth patient with the cblJ intracellularmetabolism of
cobalamin disorder
Herewepresent the fifth patient in the literaturewith the cblJ
defect, although besides the other four published patients at
least one other patient is known (Jesina et al., abstract P-586
in Ref. 39). Our patient presented within the first week of life
with hypotonia and poor feeding, more reminiscent of
patients 1 and 2. He also responded well to therapy including
vitamin B12, similar to patients 1, 3, and 4. Patient two’s
response was complicated by many other factors, including
delayed diagnosis, but also showed a partial clinical and met-
abolic response to cobalamin supplementation (4). As with
related disorders, this reinforces the importance of swift
diagnosis and treatment.
Our patient also had hair hypopigmentation. cblJ patient
three was noted to have prematurely gray hair (20) and patient
four to have dark brown rather than black hair (21). This con-
tinues the unusual pigmentation defects found in the cblJ dis-
Figure 5. Homology modeling of the ATPase domain of ABCD4. A, schematic of ABCD4 protein sequence (top) and topology (bottom) with location of
mutations used in the study indicated. Sequence and topology as described in Coelho et al. (4). The ATP domain highlighted in gray is the region used to
generate the homologymodel (see also supplemental Fig. S9). B, two views of the ATPase domainmodel showing secondary structures (gray ribbon), an ADP
molecule docked to the nucleotide-binding site, and the side chain of the residue (Arg-432) affected by the missense CblJ patient-five mutation.
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order, which if present may help distinguish it from other dis-
orders of intracellular cobalamin metabolism.
FACS-based FRET as amethod to detect interaction
We have shown that specific interaction of LMBD1 and
ABCD4 can be demonstrated using overexpression of each pro-
tein tagged to GFP and fRFP, respectively, and detected by a
flow cytometer. Flow cytometry-based FRET has been used
previously to detect protein-protein interactions (e.g. Ref. 37,
40, and 41), primarily relying on cyan fluorescent protein (CFP)
and yellow fluorescent protein (YFP) as conjugate pairs. Here,
we show that a combination of GFP and fRFP can also be used,
further opening this method to almost any flow cytometer cur-
rently in use. Although it is generally recommended to try both
N-terminal and C-terminal fluorescent protein fusions, this
may not be feasible for investigation ofmembrane proteins.We
used exclusively C-terminal fusions, as only the C termini of all
four proteins studied were predicted to extend into the cytosol
(ABCD4, Ref 4; LMBD1, Ref. 5; LAMP1, Ref. 42; ABCB9, Ref.
43), thus enabling us to avoid signal loss frommeasuring FRET
across a lipid membrane or from decreased enhanced GFP
emission intensity from low pH conditions (44) as is found
inside late endosomes and lysosomes.
Potential cellular location of the LMBD1–ABCD4 complex
There are discrepancies within the literature concerning the
cellular location of both LMBD1 andABCD4. LMBD1 has been
shown to localize to the lysosome (5), although a later study
using surface protein biotinylation found that 3–4% of
LMBD1 is located at the plasma membrane (15). We provide
additional evidence of lysosomal localization via colocalization
of LMBD1 with LAMP1 and LysoTracker using confocal
microscopy. Our experiments cannot rule out that a small per-
centage of LMBD1 may also reside at the plasma membrane.
Overexpressed ABCD4 alone has been reported to localize to
the endoplasmic reticulum based on two papers from the same
group (30, 31). Also using overexpression, here no convincing
colocalization with the ER was observed. Indeed, in all experi-
ments WT ABCD4-fRFP was found with a punctate distribu-
tion in the perinucleus and across the cytoplasm. Classical
routes for protein sorting to the lysosomalmembrane consist of
(i) the biosynthetic route, which involves secretion from the
trans-Golgi network via late endosomes, with or without pass-
ing through early endosomes, and (ii) the endocytic route,
which requires invagination from the plasma membrane with
transition from early to late endosomes (45, 46). However, no
colocalization ofABCD4withmarkers of the early, late, or recy-
cling endosomes was found. Instead, the greatest overlap we
found was between ABCD4-fRFP and LC3, a marker of
autophagosomes. This autophagosomal localizationmight rep-
resent the degradation of ABCD4 molecules overexpressed in
the absence of LMBD1, whereas the ER localization found by
other groupsmight represent an earlier stage of ER retention by
the protein quality control. It is thus tempting to speculate that
ABCD4 molecules are unstable and, possibly, misfolded when
they do not associate with LMBD1, suggesting a protective
function of LMBD1 for ABCD4 in addition to mediating lyso-
somal targeting. Future experiments may clarify this potential
secondary role for LMBD1.
We observed convincing co-localization between overex-
pressed WT ABCD4-fRFP and LMBD1-GFP in all cells exam-
ined. Based on further colocalization with LAMP1, this inter-
action appears to take place in the lysosomalmembrane. This is
consistent with the inability of cells with dysfunctional LMBD1
or ABCD4 to import cobalamin from the lysosome to the cyto-
sol and supports the role of this protein complex as necessary
for this export. This colocalization is consistent with previous
studies (4) as is the requirement of LMBD1 to support ABCD4
lysosomal targeting (31).
Expression of ABCD4-fRFP alone resulted in increased
AdoCbl and MeCbl cofactor synthesis in cblJ patient fibro-
blasts. Unexpectedly, cofactor synthesis was not further
increased by co-transfection with LMBD1-GFP. Although we
cannot rule out that some ABCD4-fRFP makes its way to the
lysosome, aided by the low levels of endogenous LMBD1
expected to be present in these cells, based on our colocaliza-
tion results, co-expression with LMBD1-GFP would be
expected to further increase lysosomal targeting. The lack of
increased cofactor synthesis in the co-transfected cells suggests
either that the small amount of correctly targeted ABCD4 is
enough tomediate Cbl cofactor synthesis in these cells or that a
step downstream in the Cbl pathway is already saturated.
Mutational interference of protein-protein interaction
We constructed mutations within theWalker A andWalker
B motifs of ABCD4. Single mutations affecting the Walker A
motif (p.Gly426Ala and p.Lys427Leu; supplemental Fig. S8) did
not have a large effect on either protein function, as determined
by the CCS assay, or interaction with LMBD1. In contrast the
double mutation (p.Gly426_Lys427delinsAlaLeu) and the
Walker B mutation (p.Asp548Asn) severely inhibited both
function and interaction. These results strongly support the
idea that ATPase activity of ABCD4 is required for interaction
with LMBD1. Nucleotide-sensitive interaction has been docu-
mented for the association of ABCC8 or ABCC9 (also called
SUR1 and SUR2)withKir6.2, which together compose anATP-
sensitive potassium ion channel (47). In this complex, ATPase
activity of the ABC transporters is translated into ion channel
opening of the associated Kir6.2-composed channel (48).
Within the intracellular B12 metabolic pathway, interaction of
the solublemitochondrial proteinsMMAAandMUT is depen-
dent on GTP-binding of MMAA (49). In both cases and per-
haps for ABCD4 as well, nucleotide-binding and/or cleavage
results in conformational changes to which its associated pro-
tein is sensitive.
Recapitulation of the patient mutations p.Asn141Lys and
p.Arg432Gln gave similar but less severe results. FRET-positive
signal was decreased compared with WT ABCD4 for both
mutant proteins but not completely abolished, in line with
decreased but still detectable cofactor synthesis. This decreased
signal is unlikely to be due to proteinmisfolding, as the amount
of ABCD-fRFP detected in the FACS assay and Western blot
was only slightly decreased for the mutant proteins compared
with that of wild type. The mutant proteins were also able to
reach the lysosome, as indicated by colocalizationwith LMBD1.
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Therefore, the dysfunction caused by these mutations likely
relates to a loss of function, e.g. p.Arg432Gln lies very close to
the ATPase Walker A site, or, more likely, the decreased inter-
action with LMBD1. Consistent with the latter explanation,
our homology model predicts Arg-432 to face away from the
nucleotide on an -helix that is accessible to the surface for
protein-binding. This mutation, then, may fall in line with the
“interaction-breaking”-type mutations. Because protein-pro-
tein interactions are increasingly recognized as crucial for
proper intracellular cobalamin cofactor synthesis within the
mitochondrial (49) and cytosolic B12 pathways (9, 50), it follows
that the same would be true for the lysosome, and any muta-
tional disruption of these interactions, in a manner similar to
the other parts of the pathway (9, 49), results in disease.
Experimental procedures
Cloning of expression vectors
DNA fragments encoding LMBD1 and ABCD4 in pTracer-
CMV2, as described in Coelho et al. (4), as well as LAMP1
(Addgene plasmid: 34831; Ref. 51) and ABCB9 (OriGene)
were amplified and cloned in-frame with a C-terminal green
fluorescent protein (GFP; pEGFP-N1, Clontech) or a fRFP
(pmKate2-N, Evrogen) using the primers and restriction sites
outlined in supplemental Table S1. A DNA fragment encoding
ABCD3 (Origene) was amplified and cloned in-frame with
C-terminal GFP (pEGFP-N1) using the primers and restriction
sites outlined in supplemental Table S1. GFP fused to fRFP was
created by amplification of GFP from pEGFP-N1 and cloned
into pmKate2-N using the primers and restriction sites out-
lined in supplemental Table S1. LMBD1-GFP fused to ABCD4-
fRFP was created by cutting out LMBD1-GFP from pEGFP-N1
using HindIII and annealing it into ABCD4-fRFP pre-cut with
HindIII. An in-frame linkerwas then inserted betweenGFP and
ABCD4 containing the protein sequence (GGGGS)3 using the
overlapping DNA sequences (forward) 5-GTACAAGTATG-
GCGGAGGTGGATCTGGCGGAGGTGGATCGGGCGGA-
GGTGGATCAAGCTTT-3 and (reverse) 5-GTACAAAGC-
TTGATCCACCTCCGCCCGATCCACCTCCGCCAGATC-
CACCTCCGCCATACTT-3 and cutting with the restriction
enzymes BsrGI and HindIII. Site-directedmutations were con-
structed with the QuikChange mutagenesis kit (Stratagene),
with primers available upon request. EEA (in pEGFP-C1,
Ref. 52), Rab7 (in pEGFP-C1, Ref. 53), and Rab11 (in pEGFP-
C1, Ref. 53) were purchased from Addgene. All constructs
were confirmed by Sanger sequencing and prepared using
the Plasmid Maxi kit (Qiagen) following the manufacturer’s
instructions.
Cell culture and expression
Immortalized and primary patient fibroblasts and immortal-
ized control fibroblasts were grown in Dulbecco’s-modified
Eagle’s medium (DMEM; Gibco) supplemented with 10% fetal
calf serum (FCS; Gibco) and antibiotics (PAA). HeLa cells were
cultured in DMEM 4.5 g/liter glucose supplemented with 10%
FBS and 1% penicillin/streptomycin. All cells were cultured at
37 °C with 5% CO2. HeLa cells were transfected by lipofection
with Lipofectamine 2000 (Thermo Fisher Scientific) according
to the manufacturer’s instructions. For fibroblasts, electropo-
ration was performed as described previously (54) using 15–25
g of DNA for single transfections and, in co-transfections,
10–12.5 g of DNA per donor construct and 10–12.5 g of
DNA per acceptor construct.
Flow cytometry-based FRET
Flow cytometry measurements were performed 30–40 h
post transfection using a FACSAriaIII (BD Bioscience). Trans-
fected cells were excited at 488 nm and 561 nm; photomulti-
plier tube (PMT), voltages and compensation for GFP and fRFP
were adjusted using the BD FACSDiva 7.0 software. GFP was
excited with the 488-nm laser and measured with a 540/30 fil-
ter; any occurring FRET signal was measured with a 695/40
filter. fRFP was excited with the 561-nm laser and measured
with a 610/20 filter. For each sample 30,000 events were col-
lected. Data were analyzed and visualized using FlowJo (version
10) software. Experiments were performed in immortalized
wild-type and cblJ02 and cblF fibroblasts. Because we found no
difference in FRET-positive signal based on cell lineage, the
data for experiments in each cell type were pooled.
Confocal and epifluorescencemicroscopy
To analyze subcellular localization, immortalized control
fibroblasts or HeLa cells co-transfected with selected con-
structs were grown on glass slides (CultureSlides; BD Falcon),
fixed after 30–40 h post transfection with 4% paraformalde-
hyde for 20min, washed 3 times in PBS (10mMNa2HPO4, 2mM
KH2PO4, 137 mM NaCl, 2.7 mM KCl), and mounted onto a
coverslip using SlowFade Gold antifade mountant (S36939;
Molecular Probes) containing 4-6-diamidion-2-phenylindole
(DAPI) for nuclear staining. For antibody staining of anti-
HSP47, cells were fixed in ice-cold methanol for 5 min, washed
3 times in PBS, and incubated in blocking buffer (10% FCS, 0.1%
Tween 20 in PBS) for 1 h at room temperature. For all other
antibodies, the cells were fixed with 4% paraformaldehyde,
washed 3	 in PBS, and permeabilized with 0.1% Triton X-100
in PBS for 15min followed by 3	washing with PBS containing
100 mM glycine and incubation in blocking buffer (10% FCS,
0.1% Tween 20 in PBS) for 1 h at room temperature. Cells were
then incubated with primary antibody (mouse anti-HSP47,
Enzo Life Sciences, diluted 1:1000; mouse anti-LAMP1, Devel-
opmental Studies Hybridoma Bank cloneH4A3, diluted to 0.75
g/ml) in blocking buffer for 1.5 h at room temperature fol-
lowed by washing 3	 in PBS and incubation with secondary
antibody (goat anti-mouse Alexa Fluor 488 or goat anti-mouse
Alexa Fluor 405; Life Technologies) diluted 1:500 in blocking
buffer for 30 min at room temperature. After washing three
times in PBS, the coverslips were mounted onto glass slides
using ProLong Diamond antifade mountant with or without
DAPI (Life Technologies). Images were taken on a confocal
(Leica SP5) or epifluorescent microscope and analyzed by the
JACoP v2.0 plug-in for ImageJ (55).
CCS assay
Uptake of [57Co]cyanocobalamin and synthesis of the cobal-
amin coenzyme forms AdoCbl and MeCbl from [57Co]cyano-
cobalamin in intact cells were performed as described (56).
Unless otherwise specified, immortalized cblF and cblJ02 fibro-
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blastswere used for all CCS assays (formutation description see
Table 2).
Homologymodeling and ligand docking
A 3D model of the ATPase domain of human ABCD4 (resi-
dues 386–605) was built usingModeler9v8 (57) and the crystal
structure of the multiple sugar binding transport ATP-binding
protein from P. horikoshii (PDB ID 2D62). To optimize the
alignment between these two sequences, a multiple alignment
including another crystallized ABC transporter, the peptidase-
containing ABC transporter PCAT1 from R. thermocellum (ID
4RY2), homologous to human ABCD4 beyond the ATPase
domain (22% identity over 398 amino acids), was made using
Clustal Omega andmanually refined to superimpose secondary
structures of the two crystallized proteins. The ATPase
domains of human ABCD4 and of the P. horikoshii multiple
sugar transporter show 30% identity and 35% similarity. One-
hundred 3D models were generated and evaluated by their
DOPE (Discrete Optimized Protein Energy) and GA341 scores
calculated byModeler. Validation steps were applied to the five
best models (corresponding to the lowest DOPE scores) using
PROCHECK (58), WHAT_CHECK (59), ERRAT (60), and
VERIFY_3D (61). The finalmodel was the best one according to
a compromise between the four programs.
This 3D model was then refined by several cycles of minimi-
zation and equilibrated by molecular dynamics simulations
(1-ns runs) using the CHARMm force field. Bonds involving
hydrogen atoms were constrained using the SHAKE algorithm
(62). At the end of each optimization, the final structure was
controlled using PROCHECK and VERIFY_3D. The Ram-
achandran plot of the final 3D model showed 86% (188/220)
favored, 12% (27/220) allowed, and 2% (2 Glu and 3 Gly) disal-
lowed residues. A solvent box with a periodic boundary of 9 Å
was added to the ABCD4model. Solvation was completed with
0.145MKCl using theDS 4.5 solvation protocol. Themodel was
then minimized using Adopted Basis NR algorithm with an
average gradient 0.001 kcal/molÅ. Nonspecific water mole-
cules were removed, andADPmolecules were docked to the 3D
model using C-Docker (63) from Discovery Studio 4.5 (Accel-
rys, Dassault Systems Biovia, Meudon, France), with default
parameters and a sphere radius of 10 Å. The poses showing the
lowest cDocker interaction energy as the scoring function were
retained and clustered according to their binding mode.
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